News

The first cohort of the SHIGATEC trial compares standard of care combined with a low dose of Shigamabs (1 mg/kg/dose) versus standard of care with placebo, in patients

With this acquisition, Teva will own around 550 products of Taiyo including all its local regulatory expertise and production facility in Japan. The acquisition also allows Teva to

Sucanon, an oral medication for type-2 diabetes, is a member of a class of diabetic medications called insulin sensitizers which help the body to make better usage of

Astellas has filed a notice of application to the Patented Medicine (Notice of Compliance) Regulations in Canada against Sandoz Canada related to the filing of an abbreviated new

The new facility will be made in 35000sqft area HCL’s Jurong Development Center in Singapore and is expected to be run under collaborations with educational and academic research

The grant will help the company in the intended dosing conversion study of CD-LD ER to IPX066 in pateints with advanced PD pateints. The company is also set

The patent applications entitled, ‘Compositions to Effect Neuronal Growth,’ include three new compounds and also cover both structure and method claims for inducing neurogenesis and the growth of

The sNDA was submitted to the FDA on 6 May 2011 by Eisai. The submission of the application was supported by the results of Phase III trial compared

The tie up aims to deliver a target list of compounds suitable for taking forward for further development. IVCC chief operating officer Tom McLean said this project joins